Moderna presents phase 1/2 mRNA-4359 melanoma data with pembrolizumab at AACR

Moderna

Moderna

MRNA

0.00
  • Moderna presented results from phase 1/2 study of investigational cancer antigen therapy mRNA-4359 at American Association for Cancer Research annual meeting on May 11, 2026.
  • Update covered safety, efficacy, translational findings from phase 2 dose-expansion cohort testing mRNA-4359 with pembrolizumab as first-line treatment in locally advanced or metastatic melanoma.
  • Readout showed immune activity consistent with therapy’s intended mechanism, supporting continued clinical development in melanoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.